Skip to content
PeptideAI
Human RCTimmunecognitioninflammationlongevity

Colostrinin

A proline-rich polypeptide complex from colostrum, taken sublingually, that modulates cytokine balance and has been trialled in mild Alzheimer's disease with modest results.

Also known as proline-rich polypeptide, PRP, CLN, colostrum polypeptide complex, Colostrinin

Human RCT — Randomised controlled trials in humans, but not an approved product for this use.

Unusually for this corner of the field there are real randomised, placebo-controlled human trials - Polish work in mild to moderate Alzheimer's disease showed stabilisation on MMSE and ADL scales versus decline on placebo over 15 weeks. The trials were small, results were modest, and a larger multicentre replication was much less impressive. Solid signal, weak magnitude.

How it works

Colostrinin is not a single molecule - it is a defined fraction of proline-rich polypeptides isolated from colostrum, mostly in the low kilodalton range, which is why no single molecular weight can be honestly quoted. Its best-documented action is bidirectional cytokine regulation: it induces interferon-gamma, TNF-alpha and IL-6 in resting cells while suppressing them in over-activated ones, producing a normalising rather than stimulating effect. In neuronal cell models it reduces reactive oxygen species, inhibits beta-amyloid aggregation and protects against amyloid-induced toxicity, and in rodent work it improves learning and behaviour in aged animals. The interest in it as a nootropic descends from that neuronal work plus one genuine randomised human trial in Alzheimer's disease.

Targets: IFN-gamma / TNF-alpha / IL-6 balance, Reactive oxygen species, Beta-amyloid aggregation

Dosing

ProtocolDoseFrequencyRoute
Alzheimer's trial protocolDissolved under the tongue, away from food.100 mcgevery second day for three weeks, then a three-week breaksublingual
General immune-support useMorning.100 mcg – 200 mcgevery second daysublingual
  • · The cycling pattern - 100 mcg every other day for three weeks, then three weeks off - is what was actually used in the published trials, not a wellness-industry invention.
  • · Commercial tablets are typically 100 mcg of the polypeptide fraction. Doses far above this have not been studied and there is no reason to think more is better with a bidirectional immunomodulator.

Cycling

Three weeks on, three weeks off is the pattern used in the human trials and is worth copying rather than dosing continuously.

Work out your exact syringe units →

Pharmacology

Half-life
Not characterised; it is a polypeptide mixture absorbed across the oral mucosa rather than a single-molecule drug.
Onset
The Alzheimer's trial measured differences at around 15 weeks, so weeks to months rather than days.
Routes
sublingual, oral
Molecule
Heterogeneous proline-rich polypeptide complex from ovine or bovine colostrum

Handling

Diluent
Not applicable
Lyophilised
Not applicable - tablets stored at room temperature, away from humidity.
Reconstituted
Not applicable.

Mixing

Sold as sublingual tablets or lozenges; nothing to reconstitute.

Side effects

  • uncommonTransient tiredness or headache in the first days— Reported in the Alzheimer's trials and settled without stopping treatment.
  • uncommonMild gastrointestinal upset
  • rareDairy protein reaction— It is colostrum-derived - a genuine milk protein allergy is a real risk here.

Do not use if

  • Cow's milk protein allergy - the source material is colostrum.
  • Severe lactose intolerance may matter depending on the preparation's excipients.

Combining it

  • synergylactoferrin — Both colostrum-derived immune modulators; commonly taken together and frequently present in the same raw material.
  • cautionImmunosuppressants — Theoretical opposition, though the bidirectional profile makes the direction of effect hard to predict.

What to monitor

  • · No routine bloodwork established; cognitive or infection-frequency tracking is the practical endpoint.

Legal status

Sold as a dietary supplement in the US and much of Europe; not an approved drug anywhere.

References

  • Leszek and colleagues, colostrinin in Alzheimer's disease randomised trial (Archivum Immunologiae et Therapiae Experimentalis) (trial)
  • Multicentre double-blind trial of colostrinin in mild to moderate Alzheimer's disease (trial)
  • Reviews of proline-rich polypeptide cytokine regulation (review)

Mechanism in depth

The mechanistically distinctive property of colostrinin is bidirectional cytokine regulation, and it is worth understanding precisely because it inverts the usual dose logic. In resting cells the fraction induces interferon-gamma, TNF-alpha and IL-6; in cells already over-activated it suppresses the same cytokines. The net behaviour is normalisation toward a set point rather than movement in a fixed direction. That means the usual assumption - if some helps, more helps more - has no basis here, and it also means an inflammatory marker moving either way on treatment is compatible with the mechanism, which makes the compound genuinely hard to monitor. The second arm is redox. Zablocka's group showed colostrinin modulates the enzymatic antioxidant system and influences inducible nitric oxide synthase at the protein level in mice, and in neuronal cell models the fraction reduces reactive oxygen species, inhibits beta-amyloid aggregation and protects against amyloid-induced toxicity. The Alzheimer's rationale is built on that neuronal work plus Popik's 1999 demonstration that colostrinin facilitates learning and memory in rats. Where the mechanism story runs out is at the level of a receptor - there is no identified binding partner, no cloned receptor, and no signalling cascade traced from the outside of a cell to the inside. What exists is a well-replicated set of cellular effects from one main research tradition without a molecular handle on how they happen.

What usually goes wrong

The most common disappointment is scale. The trials found statistically real but clinically modest effects, concentrated in the mildest patients, and a larger multicentre replication was considerably less impressive than the original Polish work. Anyone expecting a nootropic they can feel is going to conclude it does nothing, and they will be right about the feeling. The second issue is product identity: colostrinin is a fraction, not a molecule, so what is in a bottle depends on source species and isolation method, and 100 mcg of one manufacturer's polypeptide fraction is not necessarily 100 mcg of another's. Third, and genuinely dangerous in a small number of people: it is colostrum-derived, so a true cow's milk protein allergy can produce a serious reaction. Finally, the dosing cycle gets copied wrong constantly - the trial used three weeks on and two weeks off, not three and three - and since there is no dose-response rationale for a bidirectional modulator, taking more is not a way to compensate for a weak effect.

Bloodwork worth running

MarkerWhenWhy it matters
None validated - this is the honest answerNot applicable. Spend the money on a structured cognitive or symptom measure instead.There is no biomarker of colostrinin activity. The bidirectional cytokine mechanism means even a cytokine panel would be uninterpretable, since movement in either direction is consistent with the drug working.
A repeatable cognitive measure (MMSE, ADAS-cog or a validated app-based equivalent) if that is your indicationBaseline and at 15 weeks, matching the trial's double-blind phase.These are the actual endpoints the human trials used. ADAS-cog and IADL were the scales that separated from placebo in the 2004 multicentre study.Act if: The trial finding was stabilisation versus decline, not improvement. Judge it as 'did not get worse', which requires a genuine baseline to compare against.
Total IgE or a milk-specific IgE, only if you have any history of dairy reactionBefore starting, if there is any history.The source material is colostrum. A true cow's milk protein allergy is a real contraindication rather than a formality.Act if: Known milk protein allergy means do not take it.

Pharmacokinetics

Metabolism
Proteolytic. Proline-rich sequences are relatively resistant to standard endopeptidases, which is part of the rationale for the fraction's activity surviving oral administration at all - proline residues block cleavage by most peptidases and are why proline-rich motifs turn up repeatedly in orally active peptides.
Elimination
Not characterised.

Receptor targets

  • Cytokine network (IFN-gamma, TNF-alpha, IL-6) — No receptor identified and no binding data exist

    Bidirectional regulation - induction in resting cells, suppression in over-activated cells. This normalising rather than directional behaviour is the compound's signature and the reason dose escalation has no rationale.

  • Enzymatic antioxidant system (superoxide dismutase, catalase, glutathione peroxidase) — Not applicable

    Modulation of antioxidant enzyme activity, documented by Zablocka's group.

  • Inducible nitric oxide synthase — Not applicable

    Influenced at the protein level in mice, tying the cytokine and redox arms together.

  • Beta-amyloid aggregation (cell-free and cell models) — Not quantified

    Inhibition of aggregation and protection against amyloid-induced neuronal toxicity. This is the direct basis for the Alzheimer's trials, and it is in vitro evidence supporting a modest clinical result rather than the other way around.

Trials

  • Bilikiewicz and Gaus multicentre double-blind placebo-controlled trial of colostrinin in mild to moderate Alzheimer's disease Randomised double-blind placebo-controlled · n=105 · 15 weeks · 2004

    100 mcg sublingually on alternate days in cycles of three weeks on and two weeks off. Improvement versus placebo on ADAS-cog (p=0.02) and on instrumental activities of daily living (p=0.02) over the 15-week double-blind phase, followed by a 15-week open phase. The effect was statistically real and clinically modest, and it was concentrated in the mildest patients.

  • Leszek and colleagues, colostrinin proline-rich polypeptide complex in Alzheimer's disease (double-blind, placebo-controlled) Randomised double-blind placebo-controlled · 1999

    The original Polish trial that generated the interest. Reported stabilisation on MMSE and activities-of-daily-living scales versus decline on placebo. Participant number and duration were not confirmed from an accessible abstract in this session and are left null rather than guessed.

  • Leszek and colleagues, long-term study of colostrinin efficacy in Alzheimer's disease Open-label long-term follow-up · 2002

    Extended follow-up of the Polish cohort, reported in Medical Science Monitor.

What to expect, and when

Days 1-7: some people report transient tiredness or headache; this was seen in the trials and settled without stopping. Weeks 1-3: the first on-cycle completes. Nothing measurable is expected this early. Weeks 8-15: this is the window in which the trials detected separation from placebo on cognitive and functional scales. Fifteen weeks is the number to hold yourself to before deciding. Beyond 15 weeks: the open-label extensions ran longer, but the controlled evidence stops here.

Stacking and comparisons

Colostrinin and lactoferrin come from the same source material and are frequently present in the same raw colostrum preparation, which means people who take both are often double-dosing one of them without knowing it. Check what is actually in the product. The combination is otherwise sensible - lactoferrin works in the gut lumen on iron and bacterial membranes, colostrinin works on cytokine set-point and redox - and there is no reason to expect interference. With immunosuppressants the direction of effect is genuinely unpredictable rather than merely cautious, because a bidirectional modulator in a pharmacologically suppressed immune system could go either way. If you are pairing it with anything for cognition, the honest framing is that colostrinin's trial effect was stabilisation over 15 weeks in mild disease, which is a small enough signal that adding variables makes it undetectable.

Colostrinin is one of only three compounds in this class with genuine randomised placebo-controlled human trials - the others being thymosin alpha-1, lactoferrin, and the approved drugs. That puts it well ahead of the entire Khavinson family and ahead of tuftsin and thymulin. What it does not have is effect size: the ADAS-cog separation was p=0.02 in 105 patients over 15 weeks, and the larger replication was weaker. Compare that honestly against a cholinesterase inhibitor, which is itself a modest drug, and colostrinin is smaller still. Within this class it is the only compound whose primary human evidence is cognitive rather than immunological, and the only one whose mechanism is explicitly bidirectional in a way that makes monitoring near-impossible. Against lactoferrin, from the same source material, lactoferrin has more trials in more indications and a clearer mechanism.

Rough cost

$25–$60/month. Commercial sublingual tablets at 100 mcg of polypeptide fraction, dosed on alternate days in a three-weeks-on cycle, consume relatively little material. Supplement-market pricing rather than a verified survey.

Genuinely uncertain

  • No pharmacokinetics of any kind exist, and cannot straightforwardly exist, because colostrinin is a heterogeneous fraction rather than a single analyte.
  • No receptor or binding partner has been identified. The bidirectional cytokine effect is well described at the cellular level and completely unexplained at the molecular level.
  • The Core entry describes the trial cycle as three weeks on and three weeks off. The Bilikiewicz 2004 abstract specifies three weeks on and two weeks off. The trial version is used here.
  • Participant numbers and duration for the 1999 Leszek trial were not confirmed from an accessible abstract and are left null.
  • The relationship between the original Polish trial results and the weaker larger replication has not been formally reconciled in the literature.
  • Whether any component of the fraction crosses the blood-brain barrier is unknown, which is a substantial gap given that the primary indication is a CNS disease.
  • Batch and species variability between ovine and bovine preparations is acknowledged in the literature but not quantified, so cross-product dose equivalence is unresolved.

Papers